Time- and cost-efficient opportunity
The new platform will save both time and capital on research and development activities for life sciences companies. That is why the new platform is a unique opportunity for ambitious companies, explains Claus Stig Kallesøe, CEO of Grit42. Grit42 specialises in pre-clinical data management and is a supplier to the DK-Openscreen platform.
“First and foremost, daily work procedures and all data will be streamlined, which have enormous potential for future advanced analysis. Everyone in the industry knows how expensive it is to develop new pharmaceuticals, which is why the possibility of saving time in the screening phase will be visible on the bottom line,” says Claus Stig Kallesøe to the Danish news site, MedWatch.
DK-Openscreen is a 4.8 million EUR investment divided between the Danish Ministry of Higher Education and Science and the Technical University of Denmark, the University of Copenhagen, Aarhus University and Aalborg University.
The platform’s library will contain 50.000 compounds to begin with but the expectation is to increase this number. The Technical University of Denmark (DTU), where the compound library is located, has room for up to 200.000 drugs.